.Nature Medicine, Posted online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- drug conjugate (ADC) tisotumab vedotin led to enhanced progression-free as well as general survival, causing FDA approval and also a brand new treatment choice for individuals.